| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI)
|
Matsumoto, Kazuhiro
|
|
|
29 |
8 |
p. 1198-1203
|
article
|
| 2 |
Clinical outcomes and prognostic factors of concurrent chemoradiotherapy for anal squamous cell carcinoma in Japan
|
Takahashi, Ryo
|
|
|
29 |
8 |
p. 1161-1172
|
article
|
| 3 |
Current status and future perspective of immunotherapy for renal cell carcinoma
|
Blas, Leandro
|
|
|
29 |
8 |
p. 1105-1114
|
article
|
| 4 |
Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study
|
Hara, Shuhei
|
|
|
29 |
8 |
p. 1191-1197
|
article
|
| 5 |
Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022
|
Nozawa, Kazuki
|
|
|
29 |
8 |
p. 1074-1080
|
article
|
| 6 |
Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology
|
Hirose, Takeshi
|
|
|
29 |
8 |
p. 1081-1087
|
article
|
| 7 |
Impact of cancer cachexia on survival in patients with pancreatic cancer and the efficacy of first-line chemotherapy
|
Nishida, Tsutomu
|
|
|
29 |
8 |
p. 1204-1205
|
article
|
| 8 |
New predictors of microvascular invasion for small hepatocellular carcinoma ≤ 3 cm
|
Fukushima, Ryosuke
|
|
|
29 |
8 |
p. 1182-1190
|
article
|
| 9 |
Pancreatic cancer and sarcopenia: a narrative review of the current status
|
Tsukagoshi, Mariko
|
|
|
29 |
8 |
p. 1055-1066
|
article
|
| 10 |
Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study
|
Nosaki, Kaname
|
|
|
29 |
8 |
p. 1142-1151
|
article
|
| 11 |
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of pembrolizumab for gastric and biliary tract cancer and encorafenib and binimetinib for thyroid cancer in Japan
|
Matsumura, Noriomi
|
|
|
29 |
8 |
p. 1053-1054
|
article
|
| 12 |
Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology
|
Hirose, Takeshi
|
|
|
29 |
8 |
p. 1067-1073
|
article
|
| 13 |
Prognostic impact of the combination of p16INK4a, p21 and Immunoscore in rectal cancer
|
Nakao, Toshihiro
|
|
|
29 |
8 |
p. 1152-1160
|
article
|
| 14 |
Prognostic value of a mandibular canal staging system for primary lesions in patients with lower gingival squamous cell carcinoma: a multicenter, retrospective study
|
Yamakawa, Nobuhiro
|
|
|
29 |
8 |
p. 1122-1132
|
article
|
| 15 |
Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution
|
Kawashima, Atsunari
|
|
|
29 |
8 |
p. 1096-1104
|
article
|
| 16 |
Safety and efficacy of neoadjuvant chemotherapy with paclitaxel, carboplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma
|
Tanaka, Ryoko
|
|
|
29 |
8 |
p. 1133-1141
|
article
|
| 17 |
The efficacy and safety of anamorelin among patients with diabetes
|
Ando, Kenju
|
|
|
29 |
8 |
p. 1115-1121
|
article
|
| 18 |
Urological cancer statistics on incidence from 1975 to 2019 and mortality from 1958 to 2022 in Japan
|
Sasaki, Takeshi
|
|
|
29 |
8 |
p. 1088-1095
|
article
|
| 19 |
Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer
|
Seiki, Yusuke
|
|
|
29 |
8 |
p. 1173-1181
|
article
|
Journal description